Search hospitals > Oklahoma > Oklahoma City

Oklahoma Medical Research Foundation

Claim this profile
Oklahoma City, Oklahoma 73104
Global Leader in Systemic Lupus Erythematosus
Global Leader in Lupus
Conducts research for Multiple Sclerosis
Conducts research for Coronary Artery Disease
Conducts research for Rheumatoid Arthritis
154 reported clinical trials
6 medical researchers
Photo of Oklahoma Medical Research Foundation in Oklahoma CityPhoto of Oklahoma Medical Research Foundation in Oklahoma City

Summary

Oklahoma Medical Research Foundation is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Systemic Lupus Erythematosus, Lupus, Multiple Sclerosis, Coronary Artery Disease, Rheumatoid Arthritis and other specialties. Oklahoma Medical Research Foundation is involved with conducting 154 clinical trials across 114 conditions. There are 6 research doctors associated with this hospital, such as Gabriel Pardo, Cristina Arriens, MD, MSCS, Judith A. James, MD, PhD, and Christina Arriens, MD.

Area of expertise

1Systemic Lupus Erythematosus
Global Leader
Oklahoma Medical Research Foundation has run 38 trials for Systemic Lupus Erythematosus. Some of their research focus areas include:
ANA positive
anti-dsDNA positive
anti-Sm positive
2Lupus
Global Leader
Oklahoma Medical Research Foundation has run 31 trials for Lupus. Some of their research focus areas include:
ANA positive
dsDNA positive
anti-dsDNA positive

Top PIs

Clinical Trials running at Oklahoma Medical Research Foundation

Multiple Sclerosis
Lupus
Systemic Lupus Erythematosus
Shingles
Neuromyelitis Optica (NMO)
Nephritis
Lupus Nephritis
Image of trial facility.

Ocrelizumab

for Multiple Sclerosis

This trial is testing if patients with early relapsing multiple sclerosis can stop taking Ocrelizumab after initial treatment without their disease getting worse. Ocrelizumab is a medication given through an IV that helps manage multiple sclerosis by reducing harmful immune cells. The study will monitor patients for new disease activity over several years.
Recruiting2 awards Phase 4
Image of trial facility.

Frexalimab

for Multiple Sclerosis

This trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.
Recruiting1 award Phase 34 criteria
Image of trial facility.

Frexalimab

for Multiple Sclerosis

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This event-driven study will have variable duration ranging from approximately 27 to 51 months. * The study intervention duration will vary ranging from approximately 12 to 51 months. * The number of scheduled visits will be up to 27 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months.
Recruiting1 award Phase 36 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Oklahoma Medical Research Foundation?
Oklahoma Medical Research Foundation is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Systemic Lupus Erythematosus, Lupus, Multiple Sclerosis, Coronary Artery Disease, Rheumatoid Arthritis and other specialties. Oklahoma Medical Research Foundation is involved with conducting 154 clinical trials across 114 conditions. There are 6 research doctors associated with this hospital, such as Gabriel Pardo, Cristina Arriens, MD, MSCS, Judith A. James, MD, PhD, and Christina Arriens, MD.